NewsRelease
ResearchArticle Cites Cleanascite™ to Study Regulatory T Cell Survival inTumors
MONMOUTHJUNCTION, NJ,February24, 2020 -- Biotech Support Group reports on a recent researcharticle describing the simplicity and efficiency of their lipidclearance sample preparation technology for studying cell responsefactors associated with intratumoral Treg cells.The citation is:
Wang,Haiping, et al. "CD36-mediatedmetabolic adaptation supports regulatory T cell survival and functionin tumors." NatureImmunology (2020):1-11.
Depletingregulatory T cells (Treg cells) to counteract immunosuppressivefeatures of the tumor microenvironment (TME) is an attractivestrategy for cancer treatment. However, systemic impairment of theirsuppressive function limits its therapeutic potential. Elucidatingapproaches that specifically disrupt intratumoral Treg cells isdirely needed for cancer immunotherapy. The use of Cleanascite™helped demonstrate that intratumoralTreg cells increase lipid metabolism and CD36 expression.Thearticle states “cancercell-conditioned medium … was treated with Cleanascite reagent(Biotech Support Group) before Treg cell culture at a volume ratio of1:5 according to the manufacturer’s instructions.” The studyconcludes that CD36 targeting elicited additive antitumor responseswith anti-programmed cell death protein 1 therapy. The findingsuncover the unexplored metabolic adaptation that orchestrates thesurvival and functions of intratumoral Treg cells, and thetherapeutic potential of targeting this pathway for reprogramming thetumor microenvironment.
“Itsrewarding to see another reference whereby Cleanascite™ helped toidentify a characteristic feature of the tumor microenvironment. AsCleanascite™ is an aqueous suspension product without harmfulsolvents, one can use it to challenge cells for responsiveness. Thisultimately helps researchers decide whether or not lipids impartcharacteristic changes in cells, such as the relative expression ofmembrane receptors like CD36. This information will hopefully helpour understanding of how to reprogram the tumor microenvironment fortherapeutic benefit.” states Swapan Roy, Ph.D., President andFounder of Biotech Support Group.
Todownload whitepaper entitled “Cleanascite™- Lipid Removal and Cell Response Applications”,visit:
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, go tohttp://www.biotechsupportgroup.com/.
Contact:MatthewKuruc 732-274-2866, [email protected]